Biomatter
AI-powered enzyme design and development platform for industrial and chemical applications.
Biomatter is a biotech & life sciences company based in Vilnius, LT, founded in 2018. It has raised $18 million in disclosed funding. Its latest round was a Series A of $18 million in November 2026.
Overview
No overview yet. It is written from sources once there are enough of them.
Funding
Total disclosed: $18M across 1 round. Computed only from sourced rounds.
Investors
Questions and answers
What does Biomatter do?
AI-powered enzyme design and development platform for industrial and chemical applications.
How much has Biomatter raised?
Biomatter has raised $18 million in disclosed funding across 1 round tracked by OSH.
Who has invested in Biomatter?
Investors in Biomatter include Astanor, UVC Partners, Inventure Partners, and Metaplanet.
When and where was Biomatter founded?
Biomatter was founded in 2018 and is based in Vilnius, LT.
Timeline
Founded
Sources
- 1.Lithuania’s Biomatter raises $18M for AI enzyme design and a US push — thenextweb.com
- 2.MATI and IITA Partner, Biomatter Raises $18 Million | GrowinAgri Daily — growinagri.substack.com
- 3.Biomatter lands $18M to speed up enzyme development with AI — Tech.eu, Nov 12, 2026
- 4.Biomatter: $18 Million Series A To Expand AI-Designed Enzyme Platform — Pulse 2.0, Nov 12, 2026